The first plane carrying part of the Russian delegation has departed Vnukovo International Airport for Alaska (Picture: Getty)
READ MOREDeal reflects Liberty Mutual\'s conviction to its focused Asia Pacific strategy BOSTON,March 3,2025-- Liberty Mutual Insurance has agreed to sell its operations in Thailand and Vietnam to Chubb Limit
STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of reference products PROLIA® (denosumab) and XGEVA® (denosumab) respectively[1],[2]
HONG KONG,May 23,2024-- Lion Group Holding Ltd. ("Lion" or "the Company") (NASDAQ: LGHL),the operator of an all-in-one trading platform that offers a wide spectrum of products and
Expected to expand global business in the Chinese market SEOUL,South Korea,May 24,2024-- SEMIFIVE,a leading design solution provider and pioneer of platform-based custom silicon solutions,has announc
Set in the Warhammer 40,000: Space Marine universe,the exclusive new free-roam VR experience will be available at Zero Latency\'s 90+ venues globally.
Portal Will Enable Participants and Attendees to Book Roomsfor November Event in Baku BAKU,Azerbaijan,May 24,2024-- Azerbaijan,the host of COP29,today unveiled its interactive accommodation portal,the
MACAO,May 23,2024-- The BEYOND Expo 2024 commenced with a spectacular opening ceremony on May 22 at the Venetian Theatre in the Venetian Macao. The ceremony brought together global leaders in technolo
US-based CPTO to accelerate platform innovation SINGAPORE,May 24,2024-- OutSystems,a global leader in enterprise low-code application development,today announced Luis Blando as its Chief Product and
SUZHOU,ChinaandROCKVILLE,Md.,May 24,2024-- Ascentage Pharma (6855.HK),a global biopharmaceutical company engaged in developing novel therapies for cancer,chronic hepatitis B (CHB),and age-related dis
The unique event,which is among the first global events created to build excitement for the upcoming Olympic Games,sees French andSingaporeans athletes and artists coming together to revitalise the ic
The ELECTRA and ELEVATE studies were designed to overcome different resistance mechanisms and improve patient outcomes with oral-oral combination options.
Phase II results reveal median PFS of 12.6 months in patients with CLDN18.2 high or medium expression,including in patients with PD-L1 CPS<5.
© OfficialAffairs
